<DOC>
	<DOCNO>NCT01577082</DOCNO>
	<brief_summary>The purpose study show superiority CHF 1535 ( BDP/FF ) pMDI BDP HFA pMDI term lung function consider change baseline entire treatment period average pre-dose morning PEF adult asthmatic patient adequately control high dos ICS medium dose ICS+LABA .</brief_summary>
	<brief_title>Efficacy Safety CHF 1535 200/6µg Not Adequately Controlled Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Main Male female patient age &gt; 18 year . Patients persistent asthma optimally control ( GINA 2010 ) high dos ICS medium dose ICS+LABA stable dose least 4 week prior screen . Patients FEV1 &gt; = 40 % &lt; 80 % predicted patient normal value least 0.9 L. Patients document positive response reversibility test , define ΔFEV1 &gt; = 12 % &gt; = 200 mL baseline , within 30 minute administration 400 μg salbutamol pMDI . At screen end runin period , patient adequately control asthma accord GINA 2010 score Asthma Control Questionnaire ( ACQ ) &gt; 0.75 Main History near fatal asthma past hospitalisation asthma Intensive Care Unit frequent exacerbation ( 3 asthma exacerbations/ year ) . Hospitalisation , Emergency Room admission use systemic steroid ( 3 day ) asthma exacerbation 4 week prior screen visit runin period . Symptomatic infection low airways 4 week screen visit . Current exsmokers total cumulative exposure equal 5 packyears /or stop smoke one year less prior screen visit . Patients clinically significant abnormality 12lead ECG present QTcB interval value ECG &gt; 450 msec male &gt; 470 msec female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adults , adequately control , pre-dose morning PEF</keyword>
</DOC>